These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21747029)

  • 21. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
    Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
    Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
    Friedman JH; Berman RM; Goetz CG; Factor SA; Ondo WG; Wojcieszek J; Carson WH; Marcus RN
    Mov Disord; 2006 Dec; 21(12):2078-81. PubMed ID: 17013906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in antipsychotic use in dementia 1999-2007.
    Kales HC; Zivin K; Kim HM; Valenstein M; Chiang C; Ignacio RV; Ganoczy D; Cunningham F; Schneider LS; Blow FC
    Arch Gen Psychiatry; 2011 Feb; 68(2):190-7. PubMed ID: 21300946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?
    Pham Nguyen TP; Abraham DS; Thibault D; Weintraub D; Willis AW
    BMC Neurol; 2021 Jun; 21(1):240. PubMed ID: 34167473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
    Merims D; Balas M; Peretz C; Shabtai H; Giladi N
    Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study.
    Sawada H; Oeda T; Yamamoto K; Umemura A; Tomita S; Hayashi R; Kohsaka M; Kawamura T
    BMC Neurol; 2013 Oct; 13():145. PubMed ID: 24119306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
    Longardner K; Wright BA; Alakkas A; You H; Xu R; Liu L; Nahab FB
    PLoS One; 2023; 18(1):e0278262. PubMed ID: 36706079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Understanding of Psychosis in Parkinson's Disease.
    Ojo OO; Fernandez HH
    Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
    Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
    J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clozapine in Parkinson's disease psychosis: 5-year follow-up review.
    Klein C; Gordon J; Pollak L; Rabey JM
    Clin Neuropharmacol; 2003; 26(1):8-11. PubMed ID: 12567158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical antipsychotic drugs in the treatment of Parkinson's disease.
    Friedman JH
    J Pharm Pract; 2011 Dec; 24(6):534-40. PubMed ID: 22095576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease.
    Chekani F; Holmes HM; Johnson ML; Chen H; Sherer JT; Aparasu RR
    J Psychiatr Res; 2019 Oct; 117():116-121. PubMed ID: 31377483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.
    Leslie DL; Rosenheck RA
    Am J Psychiatry; 2002 Sep; 159(9):1534-40. PubMed ID: 12202274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
    Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
    J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Atypical antipsychotics in first-episode psychosis: a review].
    Rotgé JY; Aouizerate B; Tignol J
    Encephale; 2008 Apr; 34(2):194-204. PubMed ID: 18597729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease.
    Menza MM; Palermo B; Mark M
    Ann Clin Psychiatry; 1999 Sep; 11(3):141-4. PubMed ID: 10482124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribing Trends of Atypical Antipsychotic Drugs in an Outpatient Unit of a Child and Adolescent Clinic in Turkey.
    Yektaş Ç; Tufan AE
    Clin Neuropharmacol; 2018; 41(1):23-27. PubMed ID: 29303800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.